Annabelle Ewing's push for a Scottish medicines manufacturing hub

Global supply chains for essential medicines have been tested repeatedly since the early 2020s, leaving governments across Europe and the Indo-Pacific searching for ways to bring production back closer to home. Annabelle Ewing, the Scottish National Party candidate for Ochil and South Perthshire, has made medicines manufacturing a central plank of her platform, arguing that Scotland's life sciences sector can lead the way.

Ewing's proposal envisions a dedicated facility capable of producing active pharmaceutical ingredients, finished dose formulations, and biological therapies under the auspices of an independent Scottish government. Her background as a solicitor and former Member of Parliament at Westminster has shaped a pragmatic approach that combines legal expertise, industrial policy, and patient advocacy.

For voters both at home and abroad, the campaign offers a model of how smaller economies can build sovereign capability in critical sectors. The lessons drawn from comparable efforts in places like Melbourne and Sydney suggest that a focused national strategy, backed by patient capital and skilled workforces, can transform a regional life sciences cluster into a global contender.

A legal mind turned industrial champion

Ewing trained as a solicitor before first entering the House of Commons in 2001, and her legal background informs every aspect of her medicines agenda. She has written extensively about regulatory frameworks, intellectual property protections, and the public interest case for state involvement in pharmaceutical supply. Her parliamentary work included scrutiny of the Pharmaceutical Price Regulation Scheme and repeated advice that NHS procurement should reward domestic producers willing to invest in long-term capacity.

Following her return to the Scottish Parliament in 2011, Ewing continued her focus on consumer protection, access to justice, and industrial competitiveness. Friends and colleagues describe her as methodical, evidence-led, and unwilling to accept that small nations cannot compete with multinational giants. That temperament now defines her medicines manufacturing campaign.

The strategic case for Scottish production

Scotland already hosts a remarkable concentration of life sciences expertise, anchored by research-intensive universities in Edinburgh, Glasgow, Dundee, and Aberdeen. Ewing argues that adding a medicines manufacturing plant to this ecosystem would convert academic discovery into commercial output, retaining the economic value currently captured by overseas contract manufacturers.

Her plan also addresses resilience. When border closures disrupted shipments of generics during the pandemic, NHS Scotland faced shortages of common antibiotics and anaesthetics. A domestic facility would reduce exposure to similar shocks, much as the Australian government has sought to onshore critical production through its National Reconstruction Fund and partnerships with firms like CSL in Parkville, Melbourne.

Economic recovery as the political frame

Ewing frames the proposed plant within a broader programme of economic renewal for communities that have endured years of wage stagnation and deindustrialisation. Ochil and South Perthshire has a proud manufacturing heritage in distilling, paper, and engineering, and Ewing believes the next chapter can be written in pharmaceutical production.

She points to forecasts suggesting a single large-scale facility could create several hundred skilled roles, with a multiplier effect across packaging logistics, clinical trials, and medical device supply chains. Similar calculations have been made around the biomedical precincts of Melbourne's Parkville strip and Sydney's Macquarie Park corridor, where anchor institutions have pulled entire ecosystems of suppliers and service providers into orbit around them.

Independence, NHS Scotland, and patient benefit

A recurring theme in Ewing's advocacy is the link between Scottish sovereignty and the future of NHS Scotland. She argues that an independent Scotland would have the fiscal levers to underwrite a manufacturing plant and to negotiate trade terms that protect domestic producers without violating World Trade Organization obligations.

Patients would benefit first through reliable supply of common generics and, longer term, through Scotland's potential role in producing advanced therapies such as mRNA vaccines and monoclonal antibodies. Ewing has called for the facility to operate on a not-for-profit basis during its establishment phase, ensuring that price does not become a barrier to access.

Drawing lessons from Australian experience

Australian policymakers have grappled with similar questions and offer instructive parallels. CSL's global growth from a Melbourne-based serum laboratory to a top-tier biotech firm shows what sustained public investment can achieve. The Victorian government's support for the Parkville biomedical precinct demonstrates the value of clustering universities, hospitals, and research institutes around a manufacturing anchor.

Ewing has signalled admiration for these models and has met with diaspora investors and pharmaceutical executives in both hemispheres to discuss collaboration. Her campaign literature cites the Pharmaceutical Benefits Scheme as an example of how governments can guarantee offtake for domestic producers, giving them the demand certainty needed to scale up.

Local campaigning in Ochil and South Perthshire

The campaign has been visibly active across the constituency, with Ewing holding surgeries in Alloa, Tillicoultry, Crieff, and Perth. Door-knocking teams have raised the medicines manufacturing proposal alongside bread-and-butter concerns about GP access, ferry routes, and broadband connectivity. Constituents report that Ewing personally responds to correspondence about the proposal, often enclosing reading lists on industrial policy.

Local businesses, including several engineering firms and a precision components supplier in Tullibody, have already signalled interest in joining the supply chain once the plant is operational. Ewing sees this as confirmation that the economic case resonates beyond the life sciences sector itself.

Pathways forward

Ewing's medicines manufacturing proposal rests on actions anyone can support or scrutinise.

Engage with the campaign's published industrial strategy paper and submit written feedback before the next consultation window closes.
Contact local employers in Alloa, Tillicoultry, Crieff, and Perth to discuss workforce planning for life sciences roles.
Attend a public meeting or town hall event where Ewing and her team outline the proposed financing model.
Share the campaign's policy briefing with industry contacts in Australia, Canada, and Ireland to broaden the pool of comparative evidence.
Sign up as a volunteer caseworker to help constituents engage with the NHS Scotland procurement process.

Visit the campaign website today to download the full policy document, find your nearest event, and sign up for regular updates as Annabelle Ewing builds the case for a sovereign Scottish medicines manufacturing plant.